Loss above expectations. BioNTech SE (BNTX) reported a loss of EUR0.33 per share for Q4 2025. The loss widened versus consensus, triggering a 17.9% stock decline to US$83.89 on volume of 12.5 million shares. The adjusted net loss totaled EUR79.5 million for the quarter.
Revenue collapses year-over-year. Q4 revenue of EUR907.4 million fell 23.8% from the year-ago quarter, reflecting sharply lower COVID-19 vaccine demand. The company’s net loss of EUR305 million compared unfavorably to prior-year results. For full-year 2025, BioNTech generated EUR2.9 billion in total revenues, slightly above the prior year despite declining vaccine sales, bolstered by EUR613 million in non-contingent payments from the Bristol Myers Squibb collaboration.
Founders exit to pursue next-gen mRNA. CEO Ugur Sahin and CMO Ozlem Tureci announced plans to establish an independent company focused on next-generation mRNA technologies by year-end 2026. “We together felt really the need to address that. By Ozlem and I, focusing on this chapter, on this type of endeavor to ensure that we can use basic technologies and basic IT that comes from BioNTech to build something completely new,” Sahin explained on the earnings call. CFO Ramon Zapata emphasized continuity: “There is no split of BioNTech’s core mRNA capabilities. Our strategy and pipeline remains unchanged. We retain COMIRNATY. We retain our mRNA oncology programs.” The supervisory board has initiated searches for successors with “strong experience in late-stage development and commercial execution.”
2026 guidance signals further vaccine erosion. Management projects 2026 total revenues of EUR2.0 billion to EUR2.3 billion, down from 2025’s EUR2.9 billion, driven by lower COMIRNATY sales in both U.S. and European markets. Adjusted R&D expenses are expected to rise to EUR2.2 billion-EUR2.5 billion as the company accelerates late-stage oncology programs including pumitamig, ADCs, and mRNA immunotherapies. Adjusted SG&A expenses are guided to EUR700 million-EUR800 million, reflecting commercial infrastructure build-out ahead of anticipated oncology launches. The company ended 2025 with EUR17.2 billion in cash and securities.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.